These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 23580490)

  • 1. Sunitinib inhibits inflammatory corneal lymphangiogenesis.
    Detry B; Blacher S; Erpicum C; Paupert J; Maertens L; Maillard C; Munaut C; Sounni NE; Lambert V; Foidart JM; Rakic JM; Cataldo D; Noël A
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3082-93. PubMed ID: 23580490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.
    Bock F; Onderka J; Dietrich T; Bachmann B; Kruse FE; Paschke M; Zahn G; Cursiefen C
    Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2545-52. PubMed ID: 17525183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
    Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
    Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of MMP-2 and MMP-9 inhibits corneal lymphangiogenesis.
    Du HT; Du LL; Tang XL; Ge HY; Liu P
    Graefes Arch Clin Exp Ophthalmol; 2017 Aug; 255(8):1573-1579. PubMed ID: 28669039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical Ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis.
    Bucher F; Parthasarathy A; Bergua A; Onderka J; Regenfuss B; Cursiefen C; Bock F
    Acta Ophthalmol; 2014 Mar; 92(2):143-8. PubMed ID: 22994268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.
    Hos D; Bock F; Dietrich T; Onderka J; Kruse FE; Thierauch KH; Cursiefen C
    Invest Ophthalmol Vis Sci; 2008 May; 49(5):1836-42. PubMed ID: 18436817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sunitinib and bevacizumab on VEGF and miRNA levels on corneal neovascularization.
    Cakmak H; Gokmen E; Bozkurt G; Kocaturk T; Ergin K
    Cutan Ocul Toxicol; 2018 Jun; 37(2):191-195. PubMed ID: 28874077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation.
    Bachmann BO; Bock F; Wiegand SJ; Maruyama K; Dana MR; Kruse FE; Luetjen-Drecoll E; Cursiefen C
    Arch Ophthalmol; 2008 Jan; 126(1):71-7. PubMed ID: 18195221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imidazole-based alkaloid derivative LCB54-0009 suppresses ocular angiogenesis and lymphangiogenesis in models of experimental retinopathy and corneal neovascularization.
    Kim BH; Lee J; Choi JS; Park DY; Song HY; Park TK; Cho CH; Ye SK; Joo CK; Koh GY; Kim TY
    Br J Pharmacol; 2015 Aug; 172(15):3875-89. PubMed ID: 25917462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in corneal lymphangiogenesis.
    Mimura T; Amano S; Usui T; Kaji Y; Oshika T; Ishii Y
    Exp Eye Res; 2001 Jan; 72(1):71-8. PubMed ID: 11133184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KH902, a recombinant human VEGF receptor fusion protein, reduced the level of placental growth factor in alkali burn induced-corneal neovascularization.
    Zhou AY; Bai YJ; Zhao M; Yu WZ; Li XX
    Ophthalmic Res; 2013; 50(3):180-6. PubMed ID: 24008241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib.
    Lin T; Gong L
    Drug Des Devel Ther; 2017; 11():1147-1158. PubMed ID: 28435226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum eyedrops antagonize the anti(lymph)angiogenic effects of bevacizumab in vitro and in vivo.
    Hos D; Koch KR; Bucher F; Bock F; Cursiefen C; Heindl LM
    Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6133-42. PubMed ID: 23970469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Lymphangiogenesis and Hemangiogenesis in Corneal Inflammation by Subconjunctival Prox1 siRNA Injection in Rats.
    Rho CR; Choi JS; Seo M; Lee SK; Joo CK
    Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5871-9. PubMed ID: 26348636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Features of corneal neovascularization and lymphangiogenesis induced by different etiological factors in mice.
    Shi W; Ming C; Liu J; Wang T; Gao H
    Graefes Arch Clin Exp Ophthalmol; 2011 Jan; 249(1):55-67. PubMed ID: 20640436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
    Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H
    Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropilin-2 contributes to LPS-induced corneal inflammatory lymphangiogenesis.
    Tang X; Sun J; Du L; Du H; Wang L; Mai J; Zhang F; Liu P
    Exp Eye Res; 2016 Feb; 143():110-9. PubMed ID: 26500194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids.
    Hos D; Saban DR; Bock F; Regenfuss B; Onderka J; Masli S; Cursiefen C
    Arch Ophthalmol; 2011 Apr; 129(4):445-52. PubMed ID: 21482870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of topical everolimus and sunitinib on corneal neovascularization.
    Çakmak H; Ergin K; Bozkurt G; Kocatürk T; Evliçoğlu GE
    Cutan Ocul Toxicol; 2016; 35(2):97-103. PubMed ID: 25864572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.